search
Back to results

A Case Control Study of Resveratrol Effects in Coronary Artery Disease Patients With Metabolic Syndrome

Primary Purpose

Metabolic Syndrome, Coronary Artery Disease

Status
Completed
Phase
Not Applicable
Locations
Iran, Islamic Republic of
Study Type
Interventional
Intervention
Resveratrol (3, 4´, 5 trihydroxystilbene)
Sponsored by
Tehran University of Medical Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Metabolic Syndrome focused on measuring Coronary artery disease, Metabolic syndrome, Resveratrol, β-catenin, Wnt signaling, FOXO, MnSOD

Eligibility Criteria

40 Years - 55 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

-Three vessel coronary artery disease with metabolic syndrome based on WHO criteria

Exclusion Criteria:

  • Malignancy,
  • Myocardial infarction,
  • Unstable angina,
  • Previous coronary intervention,
  • Inflammatory diseases,
  • Diabetes,
  • Hypertension,
  • Endocrine disorders,
  • Other known chronic diseases,
  • Antioxidant therapy or vitamin supplements in the previous 12 months,
  • Smokers .

Sites / Locations

  • Islamic Republic of Iran

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

CAD, Metabolic syndrome .

Healthy subjects .

Arm Description

Arm1:coronary artery disease with metabolic syndrome . Intervention:Resveratrol (3, 4´, 5 trihydroxystilbene), 50 micromolar,12hour treatment . Each experiment repeats three times .

Arm2:healthy subjects Intervention:Resveratrol (3, 4´, 5 trihydroxystilbene), 50 micromolar,12hour treatment . Each experiment repeats three times .

Outcomes

Primary Outcome Measures

Relative gene expression by real-time PCR (polymerase chain reaction)
PBMCs (2×106/well) are seeded in 96-well plates and undergo overnight incubation in humidified atmosphere at 37° C temperature with 5% CO2(carbon dioxide), then the medium is removed by centrifugation at 300g for 15 min and replaced with a fresh medium containing 50 micromolar resveratrol (dissolved in DMSO (Dimethyl sulfoxide)) for 12 hours. Then, RNA extraction, cDNA(complementary DNA) synthesis and real-time PCR are performed for β-catenin, MnSOD, and PPAR-delta genes .

Secondary Outcome Measures

MnSOD enzyme activity assay .
Total β-catenin protein measurement

Full Information

First Posted
May 9, 2014
Last Updated
April 30, 2017
Sponsor
Tehran University of Medical Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT02137421
Brief Title
A Case Control Study of Resveratrol Effects in Coronary Artery Disease Patients With Metabolic Syndrome
Official Title
Effects of Resveratrol on Crosstalk Between Canonical β-catenin/Wnt and FOXO Pathways in Coronary Artery Disease Patients With Metabolic Syndrome: A Case Control Study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2014
Overall Recruitment Status
Completed
Study Start Date
April 2012 (undefined)
Primary Completion Date
August 2014 (Actual)
Study Completion Date
December 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Tehran University of Medical Sciences

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of this study is to explore the role of Canonical β-catenin/Wnt and forkhead box O (FOXO) pathways by means of investigating their target genes in coronary artery disease (CAD) pathogenesis and to examine the effects of resveratrol (RES) on these pathways in CAD patients.
Detailed Description
Metabolic syndrome is a constellation of cardiovascular and metabolic risk factors including obesity, insulin resistance, hypertension and dyslipidemia. Coronary artery disease (CAD) is considerably linked with these risk factors. Oxidative stress has a major role in development of atherosclerosis that is believed as the most common pathologic process underlying CAD. The up-regulated gene-expression of free radical scavenging enzymes such as manganese superoxide dismutase (MnSOD) by members of the forkhead box O (FOXO) transcription factors is considered to be one of the paramount cell defensive mechanisms against oxidative damage. It is now well recognized that β-catenin binds to FOXOs during oxidative stress and acts as the pivotal mediator in canonical Wnt signaling, so that it translocates to the nucleus and interacts with the family of transcription factors T-cell factor/lymphoid enhancer factor (TCF/LEF), to regulate the expression of Wnt target genes. Recent evidence suggested that the canonical Wnt signaling plays a profound role in regulation of lipid metabolism and glucose homeostasis. Peroxisome proliferator-activated receptor delta (PPAR-δ) is one of the Wnt target genes which is believed to be operative in cardiometabolic protection. Interestingly, it has been demonstrated that impaired Wnt signaling pathway is contributed to inflammation, foam cell formation, and endothelial dysfunction which are recognized as atherosclerosis pathogenic factors. Resveratrol (RES) (3, 4´, 5 trihydroxystilbene), a natural polyphenol with antioxidant effects can be found in red grapes and its processed drinks (e.g. red wine), peanuts, pomegranates and mulberries.Increasing body of evidence suggest a protective role for RES against CAD, however the underlying mechanisms still remain to be elucidated. We perform this study on 10 metabolic syndrome patients with three-vessel CAD and 10 sex-aged matched (men with 40-55 years old) healthy subjects as controls. The effects of RES on β-Catenin, manganese superoxide dismutase (MnSOD), and peroxisome proliferator-activated receptor delta (PPAR-δ) expression are evaluated in peripheral blood mononuclear cells (PBMCs) of participants.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome, Coronary Artery Disease
Keywords
Coronary artery disease, Metabolic syndrome, Resveratrol, β-catenin, Wnt signaling, FOXO, MnSOD

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CAD, Metabolic syndrome .
Arm Type
Experimental
Arm Description
Arm1:coronary artery disease with metabolic syndrome . Intervention:Resveratrol (3, 4´, 5 trihydroxystilbene), 50 micromolar,12hour treatment . Each experiment repeats three times .
Arm Title
Healthy subjects .
Arm Type
Experimental
Arm Description
Arm2:healthy subjects Intervention:Resveratrol (3, 4´, 5 trihydroxystilbene), 50 micromolar,12hour treatment . Each experiment repeats three times .
Intervention Type
Dietary Supplement
Intervention Name(s)
Resveratrol (3, 4´, 5 trihydroxystilbene)
Intervention Description
Resveratrol (RES) (3, 4´, 5 trihydroxystilbene)
Primary Outcome Measure Information:
Title
Relative gene expression by real-time PCR (polymerase chain reaction)
Description
PBMCs (2×106/well) are seeded in 96-well plates and undergo overnight incubation in humidified atmosphere at 37° C temperature with 5% CO2(carbon dioxide), then the medium is removed by centrifugation at 300g for 15 min and replaced with a fresh medium containing 50 micromolar resveratrol (dissolved in DMSO (Dimethyl sulfoxide)) for 12 hours. Then, RNA extraction, cDNA(complementary DNA) synthesis and real-time PCR are performed for β-catenin, MnSOD, and PPAR-delta genes .
Time Frame
Change from baseline after 12-hour treatment with resveratrol
Secondary Outcome Measure Information:
Title
MnSOD enzyme activity assay .
Time Frame
Change from baseline after 12-hour treatment with resveratrol
Title
Total β-catenin protein measurement
Time Frame
Change from baseline after 12-hour treatment with resveratrol
Other Pre-specified Outcome Measures:
Title
PBMCs viability assay by MTT ( 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide ) test .
Time Frame
Change from baseline after 12 and 24-hour treatment with resveratrol

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: -Three vessel coronary artery disease with metabolic syndrome based on WHO criteria Exclusion Criteria: Malignancy, Myocardial infarction, Unstable angina, Previous coronary intervention, Inflammatory diseases, Diabetes, Hypertension, Endocrine disorders, Other known chronic diseases, Antioxidant therapy or vitamin supplements in the previous 12 months, Smokers .
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Taghi Golmohammadi, PhD
Organizational Affiliation
Tehran University of Medical Sciences
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Arash Hosseinnejad, MD-PhD
Organizational Affiliation
Tehran University of Medical Sciences
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Reza Meshkani, PhD
Organizational Affiliation
Tehran University of Medical Sciences
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Mahmoud Shirzad, MD
Organizational Affiliation
Tehran Heart Center,Tehran University of Medical Sciences
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Mehrnoosh Shanaki Bavarsad, PhD student
Organizational Affiliation
Tehran University of Medical Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Islamic Republic of Iran
City
Tehran
Country
Iran, Islamic Republic of

12. IPD Sharing Statement

Learn more about this trial

A Case Control Study of Resveratrol Effects in Coronary Artery Disease Patients With Metabolic Syndrome

We'll reach out to this number within 24 hrs